New First-in-Class Phase 3 Data Demonstrate TREMFYA®▼ (guselkumab) Maintained Skin Clearance Rates Through Nearly 5 Years of Continuous Use in Adult Patients with Moderate to Severe Plaque Psoriasis
- EMEA Innovative Medicine
- New First-in-Class Phase 3 Data Demonstrate TREMFYA®▼ (guselkumab) Maintained Skin Clearance Rates Through Nearly 5 Years of Continuous Use in Adult Patients with Moderate to Severe Plaque Psoriasis
New First-in-Class Phase 3 Data Demonstrate TREMFYA®▼ (guselkumab) Maintained Skin Clearance Rates Through Nearly 5 Years of Continuous Use in Adult Patients with Moderate to Severe Plaque Psoriasis
- X (Twitter)
Copy link